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Diabetic retinopathy (DR) is the commonest cause of blindness in the working-age population of the developed world. The
molecular pathophysiology of DR is complex, and a complete spatiotemporal model of the disease is still being elucidated.
Recently, a role for angiopoietin (Ang) proteins in the pathophysiology of DR has been proposed by several research groups,
and several aspects of Ang signalling are being explored as novel therapeutic strategies. Here, we review the role of the Ang
proteins in two important forms of DR, diabetic macular oedema and proliferative diabetic retinopathy. The function of the
Ang proteins in regulating blood vessel permeability and neovascularisation is discussed, and we also evaluate recent preclinical
and clinical studies highlighting the potential benefits of modulating Ang signalling as a treatment for DR.
1. Introduction to Diabetic Retinopathy
Diabetic retinopathy (DR) is the commonest cause of blind-
ness in the working-age population of the developed world
[1]. Around 90 million people are thought to be affected by
DR, and this figure is expected to rise over the coming
decades with the rapidly increasing prevalence of obesity
worldwide and an ageing population with diabetes [1].
Two subgroups of DR account for most diabetic visual
loss, namely, proliferative diabetic retinopathy (pDR) and
diabetic macular oedema (DMO). In pDR, retinal neovascu-
larisation is prominent and the onset of dysregulated angio-
genesis is considered a hallmark feature [2]. In DMO,
retinal vascular hyperpermeability leads to the leakage of
blood plasma components into the retina [3]. In the early
stages of DR, patients are often asymptomatic, but as the dis-
ease severity progresses over time, they frequently report
visual disturbances such as blurred vision and in some cases,
severe loss of vision due to complications including vitreous
haemorrhage or tractional retinal detachment [4].
The molecular pathophysiology of DR is complex, and a
detailed spatiotemporal model of the disease is still being elu-
cidated. In patients with type I and type II diabetes mellitus
(DM), poor glycaemic control leads to hyperglycaemia,
which in turn drives aberrant regulation of at least five key
biochemical pathways. These are the polyol pathway, the
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protein kinase C (PKC) pathway, advanced glycation end
product (AGE) formation, the hexosamine pathway, and
poly (ADP-ribose) polymerase upregulation [5]. Dysregula-
tion of these pathways exacerbates oxidative stress, for exam-
ple, with increased production of reactive oxygen species
(ROS), which in turn leads to mitochondrial dysfunction,
inflammation, and hypoxia. As a result, there is upregulation
of vascular endothelial growth factor (VEGF), which has
been implicated as a key causative factor of retinal neovascu-
larisation and vascular hyperpermeability in pDR and DMO,
respectively [5–8].
Currently, a number of treatments are available to
clinicians for DR, including the optimisation of glycaemic
control with regular injections of insulin, glucocorticoid
therapy, PKC inhibitors, fenofibrate, laser photocoagulation,
and in selected cases, vitreoretinal surgery [9–13]. More
recently, anti-VEGF antibody treatments have become avail-
able, and these have demonstrated significant improvements
in patient outcomes when compared to conventional thera-
peutic options [14].
Despite these advances, visual loss due to DR remains a
major public health issue, and efforts are still underway to
develop novel treatments for DR to address this unmet
medical need. In recent years, a number of preclinical and
clinical programmes have described the use of nonsteroidal
anti-inflammatory drugs (NSAIDs), antibiotics, immuno-
suppressants, oxidative stress inhibitors, and vitriol viscosity
inhibitors for treating DR [15–18]. Furthermore, the angio-
poietin (Ang)/Tie2 signalling axis has emerged as a poten-
tial therapeutic strategy, and a number of clinical trials
have demonstrated the efficacy of a number of pharmaco-
logic and biologic mediators of the Ang/Tie2 pathway [19].
2. The Angiopoietin/Tie2 Signalling Axis
The Ang/Tie2 signalling axis is a key regulator of angiogene-
sis. Whilst the VEGF pathway is thought to be important for
inducing endothelial cell sprouting and primary network for-
mation, the Ang/Tie2 pathway regulates blood vessel remod-
elling and maturation in the later stages of the angiogenic
process [20].
Whilst Ang1 and Ang4 are known agonists of Tie2 recep-
tor activity, the role of Ang2 has been less certain [21, 22].
Based on more recent data, a consensus has emerged
pointing towards a role for Ang2 as a negative modulator
of Tie2 activity. Ang2 is also thought to act as a partial
agonist/antagonist of Tie2 function by acting as a compet-
itive inhibitor of Ang1 and Ang4 binding [23–25].
All Ang proteins are secreted factors that bind to the Tie2
receptor. The Tie2 receptor is highly expressed on endothelial
cells, and it is composed of immunoglobulin-like domains,
epidermal growth factor-like domains, and fibronectin type
III domains [26]. Following activation, Tie2 demonstrates
strong kinase activity and becomes phosphorylated on several
cytoplasmic tyrosine residues. This results in the down-
stream activation of a number of pathways, including the
PI3-kinase/protein kinase B (AKT) and extracellular signal-
regulated kinase (ERK) pathways, which inhibit de novo
blood vessel growth and vascular hyperpermeability [23].
Whilst a structural characterisation of the Ang4 protein is
lacking, efforts have been made to resolve the structure of
the Ang1/Tie2 and Ang2/Tie2 ligand/receptor interactions.
X-ray crystallography analysis of Ang1/Tie2 interactions,
coupled with structure-based mutagenesis, has been used to
identify molecular surfaces necessary for Tie2 activation.
The Ang fibrinogen-like domain has been shown to mediate
the Tie2 agonistic properties of Ang1, and when this domain
was transferred into Ang2, the protein developed constitutive
Tie2 phosphorylating capabilities [27, 28].
3. Pathological Consequences of
Angiopoietin Dysregulation
The Ang proteins regulate a large number of biochemical
pathways and physiological processes, and as such, they have
been implicated in a number of pathological pathways across
a broad range of diseases. Ang dysregulation has been impli-
cated in diabetic nephropathy, with aberrant Ang function
correlating with abnormal glomerular barrier filtration [29].
The role of Ang proteins in diabetic wound healing is
also an area of active research. In a streptozotocin- (STZ-)
inducedmousemodel of diabetes, Ang1 treatment was shown
to upregulate matrix metalloproteinase- (MMP-) 9 and stem
cell factor levels which were associated with improved ree-
pithelialisation, neovascularisation, and endothelial progeni-
tor cell recruitment [30]. An Ang-based peptide mimetic,
Vasculotide (Vasomune), was shown to promote endothelial
cell survival, migration, and MMP-2 synthesis in a skin-
woundmodel employing the db/db transgenic diabetic mouse
model. Decreased wound closure times and a significant
increase in granulation tissue were also reported [31].
In the lymphatic system, Ang1/Tie2 signalling was found
to attenuate oedema formation, and decreased inflammation
was seen in Ang1-overexpressing mice exposed to UVB
irradiation [32]. In the nervous system, Ang1 induced
neurite outgrowth in PC12 cells at levels comparable with
nerve growth factor (NGF). Interestingly, this effect was
shown to be β1-integrin-dependent, but Tie2-independent,
demonstrating that Ang1 is capable of binding to multiple
receptors [33].
The Ang proteins have been closely studied in oncologi-
cal models given their close association with angiogenic pro-
cesses. In a study looking at the role of Ang2 in the migration
of glioma tumour cells, Ang2 was found to bind to α5β1-
integrins on Tie2 receptor-negative cells via a specific
residue, Gln362, and this in turn upregulated focal adhesion
kinase (FAK). This Ang2/α5β1-integrin interaction was
shown to enhance the migration and invasion of the glioma
cells, suggesting an important role for Ang2 in mediating
tumour growth and metastasis [34].
4. Role of Angiopoietins in
Diabetic Retinopathy
It has become increasingly clear that Ang proteins regulate a
number of physiological systems, and dysregulation of these
pathways has important pathological consequences. This
family of proteins has been implicated in DR as mediators
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of the permeability of the blood-retinal barrier (BRB) and in
the regulation of pericyte function, angiogenesis, and apopto-
sis. Various treatment modalities used in DR are thought to
alter Ang protein levels, and the ability to specifically modu-
late Ang protein function therefore represents a promising
therapeutic strategy.
4.1. Ang Proteins as Risk Factors for Diabetic Retinopathy.
The levels of Ang1 and Ang2 proteins have been determined
in the eyes of patients with pDR and DMO, but there is little
consensus in the literature whether these levels are indepen-
dent risk factors for the development of these diabetic com-
plications. In most reports, Ang2 concentrations have been
reported to be increased in patients with both pDR and
DMO, implying a possible role in neovascularisation and
vascular hyperpermeability through attenuation of Tie2
activity [35–37]. However, one study reported lower levels
of Ang2 in pDR patients, an apparent inconsistency that
could reflect the established nature of the neovascularisation
seen in the group of patients studied [38].
Ang1 has been reported to be upregulated in DMO, but
there are conflicting data with regard to whether Ang1 is
upregulated in pDR [35, 36]. These observations are perhaps
unexpected given that a proposed function of Ang1 is to
prevent neovascularisation and vascular hyperpermeability.
Further research is needed to define the relative ratios of
Ang1 andAng2 levels in the eyes of patients with different dia-
betic complications and their pathophysiological relevance.
4.2. Role of the Ang Proteins in Regulating Blood-Retinal
Barrier Function and Vascular Permeability in DR. It is now
well established that Ang1 can induce vascular remodelling
by upregulating highly organised angiogenic processes and
by facilitating the tightening of endothelial cell junctions
[39]. In contrast to other angiogenic molecules like VEGF,
neovascularisation in the presence of Ang1 is highly ordered
and hierarchical, and Ang1 has been shown to rescue the for-
mation of a poorly remodelled and abnormally permeable
vascular network in a murine model of diabetic retinopathy
[40]. The exact mechanisms involved remain unclear, but
the effect of Ang1 could be antagonistic to that of VEGF-
induced vascular permeability. VEGF acts via Src to induce
vascular endothelial cadherin (VE-cadherin) tyrosine phos-
phorylation and subsequent internalisation, which results in
elevated endothelial cell permeability (Figure 1) [41]. By
sequestering Src, Ang1/Tie2 interactions could inhibit this
VEGF-induced effect and prevent endothelial cell permeabil-
ity [42]. In addition to Src regulation, Ang1 is also thought to
influence vascular endothelial phosphotyrosine phosphatase
(VE-PTP) activity. The current evidence points towards
Ang1 promoting the formation of Tie2/VE-PTP/VE-
cadherin complexes at the cellular membrane, thereby
preventing the dissociation of VE-PTP and VE-cadherin,
which normally increases vascular permeability via VE-
PTP-mediated VE-cadherin dephosphorylation and interna-
lisation (Figure 1) [43].
The role of Ang2 in regulating BRB function and vascular
permeability has been explored in murine models of DR. The
induction of diabetes in rats (with an STZ injection) and
human retinal endothelial cells (with 5-30mM concentra-
tions of glucose) was found to increase Ang2 mRNA levels
with an associated decrease in VE-cadherin levels (Figure 1)
[44]. Methylglyoxal is a product of the hyperglycaemia-
induced AGE pathway, and increased Ang2 expression in
the retinal pigment epithelium (RPE) was linked with abnor-
mal microvascular permeability via increased methylglyoxal
synthesis [45]. Elevated Ang2 synthesis was also correlated
with increased levels of proapoptotic BAX and decreased
levels of antiapoptotic BCL-2, indicating an important
role in endothelial cell dysfunction and apoptosis in DR
[45]. Interestingly, Ang2 has been shown to activate
β1-integrins in order to promote vascular destabilisation
via the regulation of VE-cadherin-containing cell-cell junc-
tions (Figure 1) [46].
4.3. Role of the Angiopoietins in Angiogenesis in DR. The
Ang/Tie2 signalling axis modulates the survival and migra-
tion of endothelial cells and is a key regulator of both vascular
remodelling and the maintenance of vascular integrity
[47]. Unsurprisingly, the role of Ang proteins in facilitating
angiogenesis has been implicated in a number of ocular
pathologies, including age-related macular degeneration,
neovascular glaucoma, and trachoma [48].
In the context of diabetic ocular pathology, Ang1 and
Ang2 were found to enhance the effects of VEGF-mediated
angiogenesis when assessed in vitro with a bovine retinal cap-
illary endothelial cell line-based tube formation assay [49].
However, the assumption that these two proteins upregulate
aberrant angiogenesis in pDR has recently been called into
question. Ang1 supplementation in an oxygen-induced
in vivo model of diabetic retinopathy blocked the develop-
ment of retinal disease by inhibiting aberrant angiogenesis
and vascular leakage [50]. This observation was replicated
in other biological systems strongly indicating that the
functions of Ang1 and Ang2 are dualistic [23, 51, 52]. It
has been proposed that Ang2 facilitates disease progression
in DR. Overexpression of Ang2 in transgenic mouse
models demonstrated reduced pericyte capillary coverage
and increased intraretinal neovascularisation via the inhibi-
tion of Ang1/Tie2 interactions (Figure 1). Furthermore,
Ang2 upregulation was found to increase VEGF expression,
which is a key factor in the development and progression
of diabetic angiogenesis [53]. Recent evidence points
towards Ang2 differentially regulating angiogenesis through
Tie2 and integrin signalling. Angiogenesis-activated endo-
thelial cells were found to harbour a subpopulation of
Tie2-negative integrin-overexpressing cells, and Ang2 was
bound to these integrins, inducing angiogenesis in a FAK-
and RAC-1-dependent manner (Figure 1) [54].
4.4. Role of Angiopoietins in Inducing Apoptosis in DR. Ang2
upregulation has been correlated with reduced pericyte cov-
erage and increased pericyte apoptosis (REFS). In a diabetic
rat model, Ang2 was upregulated almost 30-fold compared
with normal controls, and this upregulation preceded peri-
cyte loss. Injection of recombinant Ang2 into the eyes of nor-
mal rats also resulted in pericyte loss in a dose-dependent
manner [55].
3Journal of Diabetes Research
In retinal pericytes, Ang1 and Ang2 had opposite roles
depending on the culture conditions. In the presence of
tumour necrosis factor alpha (TNFα), Ang1 protected peri-
cytes against apoptosis whereas Ang2 accelerated the onset
of programmed cell death [56]. In mouse models of DR,
increased levels of Ang2 correlated with elevated loss of peri-
cytes, and vascular endothelial cells were implicated as a
potential source of Ang2. The latter was also found to induce
apoptosis under high glucose conditions and via the p53
pathway by binding to α3β1-integrins. It is therefore likely
that integrin binding is the mechanism by which Ang2
induces pericyte apoptosis (Figure 1) [57].
Upregulation of Ang2 enhances vascular damage during
hyperglycaemia in transgenic models of diabetic retinopathy.
Overexpression of Ang2 in nondiabetic and STZ-induced
diabetic mice significantly worsened the underlying vascular
pathology when pericyte apoptosis and acellular capillary
formation were assessed (Figure 1) [58]. These findings have
been corroborated in diabetic models investigating the effect
of nucleoside diphosphate kinase B (NDPKB) deficiency
[59]. NDPKB deficiency upregulated Ang2 expression and
protein N-acetylglucosamine modification, which is a prod-
uct of the hexosamine pathway, and this was associated with
decreased pericyte coverage and elevated acellular capillary
formation [59].
Ang2 could also induce astrocyte apoptosis via an
integrin-dependent mechanism. DR was induced in STZ
mouse models, and elevated Ang2 levels were correlated with
astrocyte loss. Interestingly, Ang2-mediated astrocyte apo-
ptosis could be inhibited with an anti-Ang2 neutralising
RPE cells
RPE-derived
VEGF
EC-derived
VEGF
Diabetic eye VEGF
Ang1
RPE-derived
Ang2
EC-derived
Ang2
Ang2
VEGF-RI/II Tie2 VE-CAD 훽1 integrins
훽-Catenin
VE-PTP
Src-mediated phosphorylation
and internalisation of VE-CAD
increase vascular
permeability in DMO
PI3KRAS
RAF
AKT
MEK
MAPK
Diabetic retina
Src
Src FAK
RAC1-GTP
Ang1-driven
prosurvival
signalling
GSK3훽
Ang2
Ang1
Diabetic endothelial cells
AKT PI3K
RAC1-GDP
Ang2 upregulation
in DR drives
BAX-mediated EC
apoptosis
Abnormal
angiogenesis in pDR
BCL2
BAX
Pericyte apoptosis
GSK3훽-mediated
astrocyte apoptosis
훽5 integrins
훽1 integrins
Pericyte
Tie2
Ang1Pericyte dropout
leads to formation
of microaneurysms
Figure 1: Overview of Ang/Tie2 signalling in the diabetic eye, including crosstalk with the VEGF pathway. EC= endothelial cell;
VE-CAD=VE-cadherin.
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antibody, and this likely occurred via a GSK3β-dependent
mechanism. Activation of GSK3β seemed to occur down-
stream of Ang2 binding to αvβ5-integrins, and in vivo injec-
tions of an anti-αvβ5-integrin antibody were sufficient to
inhibit astrocyte apoptosis in these particular STZ mouse
models (Figure 1) [60].
5. Role of Angiopoietin/Tie2 Signalling as Novel
Therapeutic Strategies
The modulation of Ang1 and Ang2 levels is an attractive
therapeutic target for DR [61]. Administration of Ang1
protects the vasculature against VEGF-induced leakage in a
number of physiological systems [62]. Overexpression of
Ang1 in a transgenic diabetic mouse model inhibited the
onset and progression of oxygen-induced neovascularisation
[63]. Ang1 also blocked VEGF-induced leakage of mannitol
from the systemic circulation into the retina (Table 1). In a
VEGF-overexpressing transgenic mouse model, Ang1 sup-
plementation prevented exudative retinal detachment, but it
did not have any effect on established retinal neovascularisa-
tion [64]. Consistent with these findings, intravitreal injec-
tions of adenovirus expressing Ang1 prevented leukocyte
adhesion, apoptosis of retinal endothelial cells, and subse-
quent breakdown of the BRB in an STZ-induced rat model
of DR [65].
Although Ang1 supplementation represents a viable
treatment option for DR, the instability and insolubility of
the Ang1 protein represent major technical challenges. Phar-
macological research is now being directed towards creating
more stable and soluble forms of Ang1 with more potent
activity. Cartilage oligomeric matrix protein- (COMP-)
Ang1 was shown to attenuate the structural and functional
hallmarks of DR in a transgenic mouse model [66]. When
delivered into the retina using an adeno-associated virus
serotype 2 (AAV2) viral vector, leukocyte adhesion and
vascular permeability were decreased and retinal neurophys-
iological responses were improved to levels similar to that of
nondiabetic control animals. AAV2.COMP-Ang1 was also
shown to enhance the therapeutic benefit of the intravitreal
delivery of endothelial colony-forming cells by facilitating
their integration into the retinal vasculature (Table 1) [66].
In order to enhance Tie2 activity with Ang1 supplemen-
tation, another strategy that is being explored is the inhibi-
tion of VE-PTP using biological and pharmacologic
modalities. Similarly, incubation of Tie2 expressing endothe-
lial cells in culture with AKB-9778, a small molecule inhibitor
of VE-PTP, resulted in increased Tie2 phosphorylation
[67, 68]. Crucially, inhibition of VE-PTP has been shown to
prevent ischaemia-induced retinal neovascularisation and
choroidal neovascularisation. When used in combination
with the anti-VEGF agent Aflibercept, an additive effect
was seen in the reduction of vascular leakage in VEGF-
overexpressing transgenic mouse models (Table 2) [68].
Cumulative experimental data supports the translational
potential of VE-PTP inhibition in the treatment of sight-
threatening pDR and DMO. In a phase IIb randomised
clinical trial (TIME-IIb) that recruited 144 patients with
DMO, patients treated with AKB-9778 showed a greater
reduction in central subfield thickness (CST) compared
with the anti-VEGF (ranibizumab) monotherapy group,
but this structural benefit did not result in a significantly
better visual outcome (Table 2) [69–73]. One possible rea-
son why AKB-9778 failed to improve visual acuity in the
DMO patients may be related to the absolute dependence
of Ang1 to activate Tie2 receptors and the potential for
significant loss in agonist concentrations through pericyte
death in this disease.
The inhibition of Ang2 as a means of elevating Tie2 phos-
phorylation and promoting vascular stabilisation has been
investigated in two clinical trials for DMO. In the phase II
RUBY trial, patients with DMO received high and low doses
of an anti-Ang2 antibody in combination with Aflibercept
(REGN910-3) or Aflibercept on its own. No additional visual
benefit was observed in the dual treatment group (Ang2 and
VEGF inhibition) compared with the Aflibercept monother-
apy group (Table 2) [72]. The BOULEVARD phase II clinical
trial investigated a bispecific antibody (RG-7716) targeting
both VEGF and Ang2 proteins. At week 24, patients receiv-
ing this experimental treatment modality showed a statisti-
cally superior gain in visual acuity compared with those
receiving ranibizumab. However, it should be noted that
the BOULEVARD trial compared RG-7716 against low-
dose (0.3mg) ranibizumab and not Aflibercept, which is
now considered the gold standard for the treatment of
DMO. Furthermore, the absolute visual benefit was relatively
modest, suggesting that a head-to-head comparison of
RG-7716 with Aflibercept might not demonstrate the superi-
ority of dual VEGF and Ang2 inhibition over conventional
treatment (Table 2) [73]. Despite only modest benefits of
Ang2 neutralisation, no clinical studies have yet examined
the benefits of elevating levels of Tie2 agonists, both to counter
loss in pericyte-derivedAng1 and to counterbalance increased
Ang2 levels.
Several preclinical studies have demonstrated the thera-
peutic benefit of modulating Tie2 signalling in DR. Although
exciting, the translational potential of this particular pathway
remains to be demonstrated, and further research into
Ang/Tie2 is needed to identify other targets that could be
manipulated either pharmacologically or with gene therapy
approaches.
6. Conclusion
The known reported effects of Ang proteins on vascular
function strongly suggest a key role in DR pathophysiology.
Multiple studies have demonstrated that interaction of Ang
proteins with the Tie2 receptor serves to mediate a number
of intracellular signalling pathways in a number of cell types,
including endothelial cells, RPE cells, and a number of neuro-
nal cell types, all of which are affected to some degree in DR.
The binding of the Ang proteins to Tie2 influences a range of
physiological events, including blood vessel permeability and
neovascularisation. In DMO, dysregulated Ang signalling is
thought to mediate destabilisation of the blood-retinal bar-
rier, whilst in pDR, it has been shown to induce pathological
neovascularisation in the retina. Preclinical and recent clini-
cal studies outlining the promising therapeutic potential of
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mediating Ang/Tie2 signalling have started to confirm Tie2
receptors as a therapeutic target for DR although no agents
which directly stimulate the receptor have so far been exam-
ined. In summary, Ang proteins play a vital role in DR and
are exciting therapeutic candidates towards the development
of new treatments for the condition.
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